STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.